Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective

Simple item page
dc.contributor.authorYadav, Poonam
dc.contributor.authorKhurana, Amit
dc.contributor.authorBhatti, Jasvinder Singh
dc.contributor.authorWeiskirchen, Ralf
dc.contributor.authorNavik, Umashanker
dc.date.accessioned2024-01-21T10:54:08Z
dc.date.accessioned2024-08-14T07:40:52Z
dc.date.available2024-01-21T10:54:08Z
dc.date.available2024-08-14T07:40:52Z
dc.date.issued2022-09-06T00:00:00
dc.description.abstractNon-alcoholic steatohepatitis (NASH) is a progressive form of Non-alcoholic fatty liver disease (NAFLD), which slowly progresses toward cirrhosis and finally leads to the development of hepatocellular carcinoma. Obesity, insulin resistance, type 2 diabetes mellitus and the metabolic syndrome are major risk factors contributing to NAFLD. Targeting these risk factors is a rational option for inhibiting NASH progression. In addition, NASH could be treated with therapies that target the metabolic abnormalities causing disease pathogenesis (such as de novo lipogenesis and insulin resistance) as well with medications targeting downstream processes such as cellular damage, apoptosis, inflammation, and fibrosis. Glucagon-like peptide (GLP-1), is an incretin hormone dysregulated in both experimental and clinical NASH, which triggers many signaling pathways including fibroblast growth factor (FGF) that augments NASH pathogenesis. Growing evidence indicates that GLP-1 in concert with FGF-21 plays crucial roles in the conservation of glucose and lipid homeostasis in metabolic disorders. In line, GLP-1 stimulation improves hepatic ballooning, steatosis, and fibrosis in NASH. A recent clinical trial on NASH patients showed that the upregulation of FGF-21 decreases liver fibrosis and hepatic steatosis, thus improving the pathogenesis of NASH. Hence, therapeutic targeting of the GLP-1/FGF axis could be therapeutically beneficial for the remission of NASH. This review outlines the significance of the GLP-1/FGF-21 axis in experimental and clinical NASH and highlights the activity of modulators targeting this axis as potential salutary agents for the treatment of NASH. � 2022 Elsevier Ltden_US
dc.identifier.doi10.1016/j.phrs.2022.106426
dc.identifier.issn10436618
dc.identifier.urihttp://10.2.3.109/handle/32116/4223
dc.identifier.urlhttps://linkinghub.elsevier.com/retrieve/pii/S1043661822003711
dc.language.isoen_USen_US
dc.publisherAcademic Pressen_US
dc.subjectFGF-21en_US
dc.subjectFibrosisen_US
dc.subjectGLP-1en_US
dc.subjectInflammationen_US
dc.subjectNAFLDen_US
dc.subjectNASHen_US
dc.titleGlucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspectiveen_US
dc.title.journalPharmacological Researchen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Human Genetics And Molecular Medicine - Research Publications